Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

An Example of Successful Patient-Reported Outcomes (PROs): Tarceva's Effect on Lung Cancer Symptoms
Author
Howard (Jack) West, MD

One of the successful examples of incorporating patient-reported outcome (PRO) measures into an important clinical trial was in the NCI-Canada study BR.21 (abstract here). This study assigned patients to either tarceva or placebo in a 2:1 randomization to the active drug:

BR.21 Schema

(Click on image to enlarge)

This study showed a 9% response rate and an improvement in median overall survival of two months with tarceva, which led to it’s US FDA approval and subsequent widespread use. While the fact that there were responses (although only 8%) and a survival benefit is very important, and probably the most important factor to many patients and oncologists, it’s important to ask whether this comes at the cost of significant side effects. Do patients need to trade quality of life for improved survival? A separate report on the BR.21 trial described PROs on this trial (abstract here).

In BR.21, patients were required to complete questionnaires that asked about a wide range of symptoms commonly seen in lung cancer, as well as global quality of life (QoL) and ability to function normally. Several questions focused on measured of cough, pain, and shortness of breath. The questionnaire was completed before starting treatment, every four weeks during treatment, four weeks after the end of treatment, and (for patients who came off of the study for reasons other than progression, such as side effects) every 12 weeks after ending the study, until progression. Completion rates were about 93% at the start, dipping down to the 80% range as the trial continued. Such a decline in returned responses is typical for QoL patient response assessments.

The symptom-based portion of the study assessment focused on pain, shortness of breath (SOB, also known as dyspnea), and cough. Importantly, the key measure was the time before progression of these symptoms rather than whether there was improvement in these symptoms. Why time to symptomatic worsening rathe than improvement in symptoms? Because you can’t have improvement if you don’t have the symptom, but everyone is a candidate for worsening of symptoms.

The results clearly demonstrated that the survival improvement with tarceva was also accompanied by a relative improvement in cancer symptoms. Specifically, while patients tended to have eventual worsening of symptoms at some point (as indicated by the downward slope of the curves below), recipients of tarceva had an average of a 1-2 month delay in their development of worsening of cough (4.9 vs. 3.7 months), SOB (2.9 vs. 4.7 months), and pain (2.8 vs. 1.9 months).

BR.21 Symptoms change

These differences were all statistically significant, and I would argue also clinically significant, even if we wish the results were better still.

In fact, patients on tarceva also often reported improvements in their symptoms. Not surprisingly, a higher proportion of patients on tarceva reported improvements than those receiving placebo (cough – 44% vs. 27%; SOB: 34% vs. 23%; pain: 42% vs. 28%). Global QoL was also reported as improved in more patients on tarceva: 35% vs. 26% (p < 0.0001, which means this is a very statistically significant difference despite the numbers not being extremely far apart). Personally, I’m pretty impressed with how well placebo fared, with about a quarter of the patients reporting improvement on a sugar pill, reinforcing why placebo-controlled trials are especially important when we assess PROs.

Finally, as with chemotherapy (see prior post), patients who had tumor shrinkage or stable disease on tarceva were also significantly more likely to have symptomatic improvement. For global QoL, physical functioning, cough, SOB, and pain, responding patients (complete or partial response) were the most likely to show symptomatic improvement, followed by patients with stable disease, and the lowest likelihood of symptomatic improvement in patients who have progression of disease:

QoL Sx and tarceva Response

But here is another example of how patients with stable disease receive benefit, along with a improved survival: just as survival is improved by 1-2 months among patients who show stable disease, 40-50% report symptomatic improvement in the absence of significant tumor shrinkage.

This work describes the beneficial effects of patient reported outcomes: the results corroborate the response and survival findings, and they show that patients can feel better and also live longer. These results are also factors that many patients generally care about: what is the chance that tarceva will make me feel better overall, and will my shortness of breath improve? But this study also includes some of the shortcomings: patients tend to return QoL questionnaires less consistently over time (and are the people who don’t respond the ones doing worst?), and there can be a very significant placebo effect. I’ll continue to cover some of the practical issues with PROs in the coming weeks.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on